Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

TB-4 vs TB-500

Structure Full 43-amino-acid peptide Synthetic 17-23 AA fragment Weekly dose 5-10 mg (loading) 3.5 mg (500 mcg daily) Contains LKKTET Yes (angiogenesis domain) No Primary use Broad tissue repair + angiogenesis Focused actin migration For the complete compariso

This comparison does not assign a generated winner or score.

  • Structure
  • Full 43-amino-acid peptide
  • Synthetic 17-23 AA fragment
  • Weekly dose
  • 5-10 mg (loading)
  • 3.5 mg (500 mcg daily)
  • Contains LKKTET
  • Yes (angiogenesis domain)
  • No
  • Primary use
  • Broad tissue repair + angiogenesis
  • Focused actin migration
  • For the complete comparison, see TB-4 vs TB-500.
More references

Related material

Comparison

Tissue Application Comparison

For tendon and ligament repair: BPC-157 has the strongest and most consistent tendon-specific evidence — documented in Achilles, patellar, and rotator cuff models with accelerated…

View details →
Comparison

Systemic vs Local Distribution

A notable difference in research design implications: TB-500 is known to distribute systemically from the injection site, travelling to distal injury locations. This systemic dist…

View details →